BLRX sam kupio nazad na 2,96$, nešto ga pumpaju
I ja nešto simbolično po istoj cijeni.
If approved, Motixafortide represents a significant advancement in SCM to the benefit of patients and payers alike, and, to that end, we remain on track to submit a New Drug Application (NDA) to the FDA in the first half of next year,"
Mr. Serlin concluded.